Reuters: Regulatory News: UK watchdog accuses GSK over pay-for-delay drug deals

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UK watchdog accuses GSK over pay-for-delay drug deals Apr 19th 2013, 06:15 LONDON, April 19 | Fri Apr 19, 2013 2:15am EDT LONDON, April 19 (Reuters) - Britain's antitrust watchdog said on Friday that GlaxoSmithKline and three generic drug companies had undermined competition by striking deals that paid the generic firms not to launch cheap copies of the antidepressant paroxetine. The Office of Fair Trading alleged GSK concluded agreements which infringed competition law with each of Alpharma, Generics (UK) and Norton Healthcare over the supply of paroxetine - a top-selling medicine sold by GSK under the brand name Seroxat.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions